Indogulf Cropsciences Posts Q1 FY27 Results; Revenue Recovers Sequentially While Focuses on Integrated Agri-Solutions
Indogulf Cropsciences Ltd., engaged in crop protection products, plant nutrients, and biologicals, announced its un-audited financial results for the quarter ended June 30, 2026. The company highlighted a sequential recovery in revenue while maintaining a concentrated focus on building an integrated agricultural portfolio.The consolidated financial data for Q1 FY27 showed key trends across various metrics:
| Particulars (₹ Million) | Q1 FY27 | Q1 FY26 | Y-o-Y% | Q4 FY26 | Q-o-Q% |
|---|---|---|---|---|---|
| Revenue from Operations | 1,685 | 1,894 | -11% | 1,508 | 12% |
| EBITDA (Excl. Other Income) | 96 | 99 | -4% | 204 | -53% |
| EBITDA Margin | 6% | 5% | 47 bps | 14% | -833bps |
| Profit after Tax (PAT) | 24 | 39 | -38% | 116 | -79% |
| PAT Margin | 1% | 2% | -57 bps | 8% | -657 bps |
| EPS (₹) | 0.4 | 0.8 | -53% | 2.3 | -83% |
Key Financial and Operational Highlights
Revenue from operations stood at ₹1,685 million in Q1 FY27, compared to ₹1,894 million in Q1 FY26. On a sequential basis, revenue increased by 12%, indicating an improvement in business momentum. The company reported that its EBITDA margin improved to 6%.In terms of operational performance and market reach, Indogulf Cropsciences detailed several robust activities across the agricultural sector:
- Agri-Solutions Portfolio: The company continues strengthening its portfolio spanning crop protection, plant nutrients, and biologicals to support farmers through the entire crop lifecycle.
- Farmer Engagement and Distribution: The company engaged over 100,000 farmers through an on-ground network supported by 100 or more IDOs (Independent Distributors). Its expansive distribution platform includes 7,000+ distributors, 192 active institutional partners, 30+ stock depots, and 333 sales and marketing personnel across India.
- Global Footprint: Indogulf maintains a presence in over 36 countries with more than 140 active overseas business partners, supported by 189 registrations.
- Manufacturing and Innovation: Manufacturing capacity utilization rose to 70% in Q1 FY27 from 52% in FY26, as the Barwasni facility continues expansion. The company has over 300 products, 1,000+ registrations, and 6 patents, with a strategic focus on biologicals and sustainable solutions.
Management Perspective
Commenting on the results, Mr. Sanjay Aggarwal, Managing Director of Indogulf Cropsciences Ltd., stated that the company entered the new fiscal year on a resilient note despite macro-market headwinds. He noted that Q1 FY27 reflected continuous progress toward building the company as a comprehensive, farmer-focused agri-solutions platform."While the operating environment remained dynamic," Mr. Aggarwal said, "we delivered a 12% sequential recovery in revenue to ₹1,685 million, while gross profit grew 12% YoY to ₹466 million and gross margin improved to 28%."
Looking ahead, management plans remain focused on strengthening biologicals, expanding differentiated and sustainable solutions, improving operational efficiencies, and growing the global presence. The company aims to be a farmer's friend across the complete crop lifecycle, from sowing to harvest.
Company Overview
Indogulf Cropsciences Ltd., founded in 1993 and headquartered in New Delhi, is involved in the manufacturing and distribution of crop protection products, plant nutrients, and biologicals. The company operates across 36+ countries, offering a diversified portfolio of over 300 products backed by more than 1,000 registrations.IGCL Stock Price Movement
Indogulf Cropsciences Limited shares settled today, shedding 1.05% to close at ₹71.87 in the post-market trading session. The stock saw a traded volume of 158,399 shares during the day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: